NervGen Pharma Corp. NGEN 深 滬
已收盤 04-02 16:00:00 美东时间
4.26
-0.100
-2.29%
華盛通- 最 高4.30
- 今 開4.23
- 成交量 61.18万股
- 最 低 4.05
- 昨 收 4.36
- 總市值 3.37亿
- 52周最高 6.30
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 3.51
- 委 比 -70.61%
- 總股本 7921.25万
- 歷史最高 6.30
- 量 比 3.45
- 振 幅 5.73%
- 歷史最低 3.51
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma reported positive updates on its NVG-291 drug candidate for chronic tetraplegia, including successful Phase 1b/2a results, significant functional improvements, and plans for a Phase 3 study in mid-2026. The company also expects to expand NVG-291 into additional clinical indications and strengthen its leadership team to support its growth. Financially, the company had $22.1M in cash as of December 2025 and continued to advance its n...
03-31 11:45
NervGen Pharma Voluntarily Delisting From TSX Venture Exchange, Effective March 16
NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other
03-13 04:28
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
NervGen Pharma Corp. has voluntarily delisted its common shares from the TSX Venture Exchange, effective March 16, 2026, to reduce costs and administrative burdens. The company will continue trading on Nasdaq under the symbol "NGEN," with no action required by shareholders. This decision aligns with NervGen’s strategic focus on advancing its lead therapeutic candidate, NVG-291, in late-stage development for spinal cord injury treatment.
03-12 20:15
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. Both bring extensive experience to support NervGen's lead therapeutic, NVG-291, which is advancing through clinical trials for spinal cord injury (SCI). Ruff, with over 30 years in regulatory affairs, will oversee the company's regulatory strategy, while McSherry will ensure p...
03-04 12:30
NervGen Pharma to Participate at Upcoming Investor Conferences
NervGen Pharma Corp., a biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury (SCI) and neurologic conditions, announced that its executives will participate in upcoming investor conferences: the Oppenheimer 36th Annual Healthcare conference on February 25th, TD Cowen’s 46th Annual Health Care conference on March 2nd, and the Leerink Partners Global Healthcare conference on March 8th-11th. The company’s lead can...
02-18 12:30
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Corp. announced that Adam Rogers, MD, has been appointed as President and CEO. The Board of Directors expressed confidence in his leadership, highlighting his successful interim tenure, including the company's Nasdaq listing. Rogers, a physician and biotech executive, is focused on advancing NVG-291, a neuroreparative peptide in late-stage development for spinal cord injury, which has received FDA Fast Track and EMA Orphan Drug des...
02-09 12:00
首日收盘|Buda Juice收涨8.13%，最新总市值1.03亿美元
Buda Juice涨8.13%，最新市值1.03亿美元；NervGen Pharma Corp Ordinary Shares涨2.23%，最新市值4.73亿美元；Bleichroeder Acquisition II涨0.30%，最新市值0.00亿美元；
01-09 06:00
